Pharmaceutical M&A came back with a bang during October, after a quiet September. Merck & Co (NYSE: MRK) and AbbVie (NYSE: ...

Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. | Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should ...

The Indo US Bridging RARE Summit 2024 will spotlight the urgent need for cross-border collaborations to address disparities in rare disease treatment by bringing together patient advocates, clinicians ...

AstraZeneca showcased positive early data on three experimental weight-loss drugs at ObesityWeek, highlighting its oral GLP-1 ...

Sanofi’s BTK inhibitor rilzabrutinib helped 23% of adults with a rare autoimmune blood disorder achieve target platelet counts in a Phase 3 trial, compared to zero patients in the placebo ...

INBX's two main pipeline candidates are entering critical late-stage trials with data readouts expected in mid- to late-2025. Click here to read my analysis.

VIR's HDV and HBV treatments remain Vir's primary value drivers, with upcoming catalysts in Q4 2024 and 2025. Find out why VIR stock is a Buy.

The global sales of hydroxypropyl distarch phosphate market are anticipated to reach a valuation of USD 1.9 billion in 2023, ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Sell rating on AstraZeneca (AZN – Research Report), with ...

Citigroup Global Markets India Pvt. Ltd. ("Manager to the Offer") has submitted to BSE a copy of Draft Letter of Offer to the Public Shareholders of Sanofi Consumer Healthcare India Ltd ("Target ...

Q3 2024 Earnings Call Transcript November 3, 2024 Operator: Good day, and welcome to the Kymera Therapeutics Third Quarter ...

Vivendi, Societe Generale, Capgemini, Kering, Pernod Ricard and Sanofi lost 1 to 1.7%. Shares of Swiss staffing company Adecco dropped nearly 6% after Q3 result missed consensus estimate. On the ...